Barbare J C, Ballet F, Petit J, Poupon R, Darnis F
Bull Cancer. 1984;71(5):442-5.
Twelve patients with unresectable hepatocellular carcinoma associated with cirrhosis were treated with Doxorubicin which was given intravenously (30 to 50 mg/m2) every three weeks. Six patients were given only one dose of Doxorubicin. No clinical response was observed. Five patients has serum alphafoetoprotein (AFP) determination during the treatment. AFP concentration rose in 4 patients and fell in 1 patient. Survival rate after 3 and 8 months of treatment was 58 and 33 per cent. These results suggest that Doxorubicin is not an effective treatment for hepatocellular carcinoma.
12例伴有肝硬化的无法切除的肝细胞癌患者接受了阿霉素治疗，每三周静脉注射一次（30至50毫克/平方米）。6例患者仅接受了一剂阿霉素。未观察到临床反应。5例患者在治疗期间进行了血清甲胎蛋白（AFP）测定。4例患者的AFP浓度升高，1例患者的AFP浓度下降。治疗3个月和8个月后的生存率分别为58%和33%。这些结果表明，阿霉素对肝细胞癌不是一种有效的治疗方法。
